Bioasis to Present at the 20th Annual BIO CEO & Investor Conference
February 06 2018 - 1:28PM
Business Wire
Bioasis Technologies, Inc. (OTCQB:BIOAF; TSX.V:BTI) announced
today that it will present at the 20th Annual BIO CEO &
Investor Conference, to be held February 12-13, 2018 at the New
York Marriott Marquis.
Mark Day, Ph.D., president and chief executive officer, Bioasis,
will present at the BIO CEO & Investor Conference as
follows:
Date: Mon., Feb. 12, 2018
Time: 3:15 p.m. ET
Room: Odets Room (4th Floor)
Venue: New York Marriott Marquis, 1535 Broadway, New
York, NY 10036 (United States)
About Bioasis
Bioasis Technologies, Inc. is a preclinical biopharmaceutical
company focused on the delivery of therapeutics across the
blood-brain barrier (BBB) and into the central nervous system for
the treatment of neurological diseases and disorders. The delivery
of therapeutics across the BBB represents the single greatest
challenge in treating neurological disorders. The company is
developing and commercializing the xB3 platform, Bioasis’
proprietary blood-brain barrier delivery technology, to address
unmet medical needs in the treatment of central nervous system
diseases and disorders. The company maintains headquarters in
Vancouver, Canada with offices in Guilford, Conn., United States.
Bioasis trades on the TSX Venture Exchange under the symbol “BTI”
and on the OTCQB under the symbol “BIOAF.” For more information
about the company please
visit www.bioasis.ca or www.bioasis.us.
About the 2018 BIO CEO & Investor Conference
The 2018 BIO CEO & Investor Conference is one of the largest
investor conferences focused on established and emerging publicly
traded and select private biotech companies. The conference, now in
its 20th year, provides a forum where institutional investors,
industry analysts, and senior biotechnology executives have the
opportunity to shape the future investment landscape of the
biotechnology industry.
About BIO
BIO is the world's largest trade association representing
biotechnology companies, academic institutions, state biotechnology
centers and related organizations across the United States and in
more than 30 other nations. BIO members are involved in the
research and development of innovative healthcare, agricultural,
industrial and environmental biotechnology products. BIO also
produces the BIO International Convention, the world’s largest
gathering of the biotechnology industry, along with
industry-leading investor and partnering meetings held around the
world. BIOtechNOW is BIO's blog chronicling “innovations
transforming our world” and the BIO Newsletter is the
organization’s bi-weekly email newsletter. Subscribe to the
BIO Newsletter.
Forward Looking Statements
Certain statements in this press release contain forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995 or forward-looking information under applicable
Canadian securities legislation that may not be based on historical
fact, including without limitation statements containing the words
“believe”, “may”, “plan”, “will”, “estimate”, “continue”,
“anticipate”, “intend”, “expect” and similar expressions. Such
forward-looking statements or information involve known and unknown
risks, uncertainties and other factors that may cause our actual
results, events or developments, or industry results, to be
materially different from any future results, events or
developments express or implied by such forward-looking statements
or information. Such factors include, among others, our stage of
development, lack of any product revenues, additional capital
requirements, risk associated with the completion of clinical
trials and obtaining regulatory approval to market our products,
the ability to protect our intellectual property, dependence on
collaborative partners and the prospects for negotiating additional
corporate collaborations or licensing arrangements and their
timing. Specifically, certain risks and uncertainties that could
cause such actual events or results expressed or implied by such
forward-looking statements and information to differ materially
from any future events or results expressed or implied by such
statements and information include, but are not limited to, the
risks and uncertainties that: products that we develop may not
succeed in preclinical or clinical trials, or future products in
our targeted corporate objectives; our future operating results are
uncertain and likely to fluctuate; we may not be able to raise
additional capital; we may not be successful in establishing
additional corporate collaborations or licensing arrangements; we
may not be able to establish marketing and the costs of launching
our products may be greater than anticipated; we have no experience
in commercial manufacturing; we may face unknown risks related to
intellectual property matters; we face increased competition from
pharmaceutical and biotechnology companies; and other factors as
described in detail in our filings with the Canadian securities
regulatory authorities at www.sedar.com. Given these risks and
uncertainties, you are cautioned not to place undue reliance on
such forward-looking statements and information, which are
qualified in their entirety by this cautionary statement. All
forward-looking statements and information made herein are based on
our current expectations and we undertake no obligation to revise
or update such forward- looking statements and information to
reflect subsequent events or circumstances, except as required by
law.
Neither the TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in the policies of the TSX
Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20180206006198/en/
Media & Investor RelationsBioasis Technologies,
Inc.Catherine London+1 917-763-2709Catherine@bioasis.us
BiOasis Technologies (TSXV:BTI)
Historical Stock Chart
From Mar 2024 to Apr 2024
BiOasis Technologies (TSXV:BTI)
Historical Stock Chart
From Apr 2023 to Apr 2024